Track market-moving stories before they get noisy

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127 million people.

The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 11 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.

More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.

This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.

About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc., develops and commercializes proprietary laboratory-developed tests such as CNSide®, which is designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of cerebrospinal fluid to inform and improve the management of patients with leptomeningeal metastases. For more information, please visit www.cnside-dx.com.

About Plus Therapeutics
Plus Therapeutics, Inc. (NASDAQ: PSTV) is a clinical-stage healthcare company advancing an integrated approach to central nervous system (“CNS”) cancers through precision therapeutics, molecular diagnostics and data-driven technologies. The Company's lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being developed for the treatment of leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers. Its CNSide® cerebrospinal fluid assay platform is designed to provide diagnostic and disease monitoring information to support the management of patients with CNS cancers. Together with its growing data and artificial intelligence capabilities, Plus Therapeutics is building an integrated CNS oncology platform intended to improve clinical decision-making, accelerate therapeutic development and advance personalized care for patients with CNS cancers.

Effective August 3, 2026, Plus Therapeutics will change its corporate name to Cerenome, Inc. and begin trading under the Nasdaq ticker symbol CNSY. Until that date, the Company will continue to operate as Plus Therapeutics and trade under the ticker symbol PSTV.

For more information, please visit www.plustherapeutics.com. Beginning August 3, 2026, additional information will be available at www.cerenome.com.

About Medical Mutual

Founded in 1934, Medical Mutual is the oldest and one of the largest health insurance companies based in Ohio. We provide peace of mind to more than 1.2 million members through our high-quality health, life, disability, dental, vision and indemnity plans. We offer fully insured and self-funded group coverage, including stop loss, as well as Medicare Advantage, Medicare Supplement, and individual plans. For more information, please visit http://www.medicalmutual.com/.

Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Investor Contact
CORE IR
[email protected]

Cohen & Steers, Inc. (CNS) Q2 2026 Earnings Call July 17, 2026 10:00 AM EDT

Company Participants

Brian Heller - Senior VP & Deputy General Counsel
Amit Muni - Chief Financial Officer
John Cheigh - President & Chief Investment Officer
Joseph Harvey - CEO & Director

Conference Call Participants

John Dunn - Evercore ISI Institutional Equities, Research Division
Macrae Sykes - Gabelli Funds, LLC

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers 2nd Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded Friday, July 17, 2026.

I would now like to turn the conference over to Brian Heller, Senior Vice President and Deputy General Counsel of Cohen & Steers. Please go ahead.

Brian Heller
Senior VP & Deputy General Counsel

Thank you, and welcome to the Cohen & Steers second quarter 2026 earnings webcast and conference call. Joining me are Joe Harvey, our Chief Executive Officer; Amit Muni, our Chief Financial Officer; and Jon Cheigh, our President and Chief Investment Officer.

I want to remind you that some of our comments and answers to your questions may include forward-looking statements. We believe these statements are reasonable based on information currently available to us, but actual outcomes could differ materially due to a number of factors, including those described in our accompanying second quarter earnings release and presentation, our most recent annual report on Form 10-K and our other SEC filings. We assume no duty to update any forward-looking statement. Further, none of our statements constitute an offer to sell or the solicitation of an offer to buy the securities of any fund or other investment vehicles. The presentation that will accompany today's webcast also contains non-GAAP financial measures referred to as as-adjusted financial measures that we believe are meaningful in evaluating our performance.

Cohen & Steers NYSE: CNS reported higher second-quarter 2026 adjusted earnings and assets under management, as executives pointed to improving demand for real estate, infrastructure, preferred securities and broader real assets strategies.

On the company’s earnings call, Chief Financial Officer Amit Muni said Cohen & Steers generated adjusted earnings per share of $0.85, up from $0.79 in the first quarter and $0.73 in the year-earlier quarter. Net income was $44 million, rising 8% sequentially and 18% from the second quarter of last year.

Assets under management increased about 8% to more than $100 billion, driven by positive market performance and net inflows. Muni said the firm generated $1.3 billion of net inflows, “one of the strongest flow quarters in our recent history,” while its institutional pipeline stood at $1.6 billion.

Get Cohen & Steers alerts:

Revenue Growth Outpaces Expense Growth Revenue increased 5% from the prior quarter to $152 million, which Muni attributed to higher average assets under management from market appreciation and net inflows. Total operating expenses rose 3% to $97 million, primarily due to higher incentive compensation accruals tied to increased revenue.

The firm’s adjusted operating margin improved to 36.3%, reflecting operating leverage as revenue growth exceeded expense growth. Muni said Cohen & Steers is maintaining its expense guidance, including compensation and benefits expenses of about 40% of revenue, mid-single-digit growth in general and administrative expenses compared with 2025 and a pro forma effective tax rate of 25% to 26%.

The company ended the quarter with $219 million of cash and U.S. Treasuries on its balance sheet, along with about $136 million of liquid seed investments across its funds. Muni said that liquidity gives the firm “substantial financial flexibility” to support capital management priorities and strategic growth initiatives.

Open-End Funds Drive Inflows Muni said net inflows were primarily driven by the firm’s open-end funds, including mutual funds, exchange-traded funds and SICAVs. In the advisory business, the company experienced modest outflows mainly related to institutional client rebalancing. The sub-advisory business generated slight net inflows, as more than $500 million of new mandates were partly offset by redemptions.

By strategy, U.S. real estate was the largest contributor to flows, complemented by demand for preferred securities and global listed infrastructure strategies.

Chief Executive Officer Joseph Harvey said the quarter reflected continued “broad positive business momentum,” with the $1.3 billion in net inflows representing the highest level in four and a half years. It was also the seventh quarter of inflows in the past eight quarters.

Harvey said that, with the exception of global real estate, every strategy recorded net inflows during the quarter. U.S. real estate led with $833 million in net inflows. The firm’s multi-strategy real assets portfolio generated $380 million in net inflows, bringing strategy-wide assets to $3 billion, which Harvey said represents a 29% compound annual growth rate since 2021.

Global listed infrastructure recorded its sixth straight quarter of inflows and is active in the institutional channel, Harvey said. Preferred securities, the firm’s second-largest strategy by AUM, posted a second consecutive quarter of inflows. Preferreds AUM stood at $18 billion, compared with a prior peak of $27 billion.

Investment Performance Mixed Over One Year, Stronger Longer Term President and Chief Investment Officer Jon Cheigh said 41%, 91% and 97% of the firm’s AUM outperformed over the one-, three- and five-year periods, respectively. Cheigh said the one-year result was an “outlier” caused solely by U.S. REIT relative performance, while other strategies, including international real estate, continued to outperform.

Within U.S. REITs, Cheigh said most short-term underperformance was driven by positioning in cell tower REITs, which have been affected by slower carrier spending following the initial 5G build-out and concerns that satellites could displace towers. He said the firm expects a return to its historical norm of 200 basis points of alpha in U.S. REITs going forward.

Cheigh also highlighted global listed infrastructure performance, saying that team outperformed by 370 basis points over the last year. He said infrastructure remains a growing area of investor interest.

Cheigh said U.S.-listed real estate returned 10.7% during the quarter and was up 14.9% year to date, while global real estate was up 9.6% for the year. Infrastructure returned 2.3% in the quarter and 10.7% year to date. Diversified real assets, despite a softer second quarter due to declines in energy prices and precious metals, were up 9.9% through the first half of the year, ahead of what Cheigh described as a roughly 6% return for a 60/40 portfolio.

Executives See Recovery in Real Estate and Real Assets Cheigh said the firm believes the real estate recovery remains underappreciated. He said property fundamentals are improving across sectors, with particular strength in senior housing and data centers. He also cited return-to-office trends in New York and San Francisco, strong retail performance after limited new supply over the past decade, recovering industrial demand and the absorption of excess residential supply.

Cheigh said U.S. and global REITs have delivered annualized returns of 10.1% and 10.7%, respectively, over the past three years. He said the firm believes double-digit returns are a sustainable forward outlook for its listed real estate strategies, even with interest rates at current or modestly higher levels.

Private real estate values have stabilized after a prolonged correction, Cheigh said, and transaction activity continues to recover. He said the NFI-ODCE Index has delivered seven consecutive quarters of positive total returns through the first quarter and appears on track for an eighth.

Cheigh also noted that Cohen & Steers Income Opportunities REIT, the firm’s non-traded REIT, has generated a 12.3% annualized total return since its 2024 inception through May, which he called industry-leading performance.

Growth Initiatives Gain Traction Harvey said the firm’s active ETF platform surpassed $1 billion in AUM. Its largest ETF is its real estate strategy, with $450 million in AUM. Harvey said the company expects to launch its seventh ETF by the fall, a version of its multi-strategy real assets portfolio.

The company’s SICAV fund platform reached $2 billion in AUM, with record net inflows of $326 million during the quarter. Harvey said inflows were led by multi-strategy real assets and global listed infrastructure, with international traction in markets including the United Kingdom, Japan and South Africa.

Harvey said the company’s unfunded institutional pipeline remained broad by strategy and geography. The $1.6 billion pipeline included allocations to global listed infrastructure, TREF, U.S. real estate, global real estate, multi-strategy real assets and private real estate, with domiciles across 11 countries.

During the question-and-answer session, Harvey said demand for U.S. real estate strategies is improving in both wealth management and institutional channels, aided by recent REIT performance and stronger fundamentals. He also said the company sees opportunities in global sub-advisory, including in the U.S., Canada, Australia and New Zealand, while noting that Japan has been more challenging recently due to local macro conditions and investor appetite for equities.

Harvey closed the call by welcoming Muni as CFO and thanking Mike Donohue for serving as interim CFO during the transition.

About Cohen & Steers (NYSE:CNS)Cohen & Steers, Inc is a publicly traded investment management firm specializing in real estate securities and alternative income strategies. Founded in 1986 by Martin Cohen and Robert Steers, the company has built a reputation for expertise in listed real estate investment trusts (REITs) and related equities. Headquartered in New York City, Cohen & Steers applies a research-driven approach to identify value and income opportunities across global property markets.

The firm offers a diverse range of investment products, including mutual funds, closed-end funds, and exchange-traded funds (ETFs).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Cohen & Steers Right Now?Before you consider Cohen & Steers, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cohen & Steers wasn't on the list.

While Cohen & Steers currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

, /PRNewswire/ -- Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") today announced the results of its transferable rights offering (the "Offer"), which commenced on June 18, 2026 and expired on July 15, 2026 (the "Expiration Date"). The Offer was led by UBS Investment Bank as the sole dealer manager.

The Offer is expected to result in the issuance of approximately 12,642,989 shares of the Fund's common stock (the "common shares") (including notices of guaranteed delivery), resulting in anticipated gross proceeds to the Fund of approximately $154 million, or $220 million after adding anticipated leverage to the gross proceeds raised. The Fund will receive the entire proceeds of the Offer since Cohen & Steers Capital Management, Inc. (the "Advisor"), the Fund's investment adviser, has agreed to pay all expenses incurred in connection with the Offer. 

The subscription price of $12.15 per common share was determined based upon the formula equal to the higher of 92.5% of the average of the last reported sales price of a common share on the New York Stock Exchange ("NYSE") on the Expiration Date and each of the four preceding trading days on the NYSE or 90% of the average of the Fund's net asset value per common share at the close of trading on the NYSE on the Expiration Date and each of the four preceding trading days (the "Subscription Price"). Common shares will be issued promptly after completion and receipt of all stockholder payments.

Joseph Harvey, Chief Executive Officer of Cohen & Steers, said:

"With the continued support of our investors, we are supplying RQI with proceeds to further capitalize on the compelling investment opportunities emerging across both listed and private real estate. I am grateful for all the investors who continue to place their trust in Cohen & Steers."

Mathew Kirschner, Portfolio Manager, U.S. Real Estate, said:

"We believe that real estate is in the early stages of a new cycle. In addition, structural tailwinds including a retail renaissance, AI-driven digital transformation, and changing demographics including an aging population, are converging with limited supply to create compelling investment opportunities across real estate. With the support of our investors, this rights offering enables RQI to invest fresh capital at what we believe are attractive valuations into these opportunities."

This document is not an offer to sell any securities and is not soliciting an offer to buy any securities in any jurisdiction where the offer or sale is not permitted. This document is not an offering, which can only be made by a prospectus. Investors should consider the Fund's investment objectives, risks, charges and expenses carefully before investing. Such information, including other information about the Fund, can be found on file with the Securities and Exchange Commission and should be read carefully before investing.

About Cohen & Steers Quality Income Realty Fund, Inc. The Fund is a diversified, closed-end management investment company registered under the Investment Company Act of 1940, as amended. The primary investment objective of the Fund is to seek high current income through investment in real estate securities. The secondary investment objective is capital appreciation. Real estate securities include common stocks, preferred stocks and other equity and debt securities issued by real estate companies, including real estate investment trusts (REITs) and similar REIT-like entities.

About Cohen & Steers, Inc. Cohen & Steers, Inc. ("Cohen & Steers") is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

The Advisor is a wholly owned subsidiary of Cohen & Steers.

Forward-Looking Statements

This press release and other statements that Cohen & Steers may make may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Safe Harbor Statement

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

Risks of Investing in Real Estate Securities

The risks of investing in real estate securities are similar to those associated with direct investments in real estate, including falling property values due to increasing vacancies; declining rents resulting from economic, legal, political or technological developments; lack of liquidity; lack of availability of financing; limited diversification, sensitivity to certain economic factors such as interest rate changes and market recessions and changes in supply of or demand for similar properties in a given market. No representation or warranty is made as to the efficacy of any particular strategy or fund or the actual returns that may be achieved.

Risks of Investing in Closed-End Funds

Shares of many closed-end funds frequently trade at a discount from their asset value. Funds are subject to stock market risk, which is the risk that stock prices overall will decline over short or long periods, adversely affecting the value of an investment in a fund.

Website: https://www.cohenandsteers.com/
Symbols: (NYSE: CNS, RQI)

SOURCE Cohen & Steers, Inc.

Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to enable longitudinal patient monitoring

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $100.1 billion as of June 30, 2026, an increase of $644 million from assets under management of $99.5 billion at May 31, 2026. The increase was due to market appreciation of $611 million and net inflows of $495 million, partially offset by distributions of $462 million.

 Assets Under Management

(unaudited)

($ in millions)

AUM

  Net

Market

 AUM

By investment vehicle:

5/31/2026

 Flows

App/(Dep)

Distributions

 6/30/2026

Institutional Accounts:

  Advisory

$22,698

$36

$171

-

$22,905

  Subadvisory

15,712

(236)

194

(52)

15,618

Total Institutional Accounts

38,410

(200)

365

(52)

38,523

Open-end Funds

48,456

695

196

(354)

48,993

Closed-end Funds

12,589

-

50

(56)

12,583

Total AUM

$99,455

$495

$611

($462)

$100,099

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

SOURCE Cohen & Steers, Inc.

, /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date.

In December 2012, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares. 

The Fund's monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund's assets. A return of capital is not taxable; rather, it reduces a shareholder's tax basis in his or her shares of the Fund. In addition, distributions from the Fund's investments in real estate investment trusts (REITs) may later be characterized as capital gains and/or a return of capital, depending on the character of the dividends reported to the Fund after year-end by REITs held by the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund's distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund's distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

June 2026

YEAR-TO-DATE (YTD)

June 30, 2026*

Source

Per Share Amount

% of Current Distribution

Per Share Amount

% of 2026 Distributions

Net Investment Income

$0.0900

100.00 %

$0.1090

20.19 %

Net Realized Short-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Net Realized Long-Term Capital Gains

$0.0000

0.00 %

$0.4310

79.81 %

Return of Capital (or other Capital Source)     

$0.0000

0.00 %

$0.0000

0.00 %

Total Current Distribution

$0.0900

100.00 %

$0.5400

100.00 %

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund's Year-to-date Cumulative Total Return for fiscal year 2026 (January 1, 2026 through May 31, 2026) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund's Cumulative Distribution Rate for 2026. In addition, the Fund's Average Annual Total Return for the five-year period ending May 31, 2026 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund's Current Annualized Distribution Rate for 2026. The performance and distribution rate information disclosed in the table is based on the Fund's net asset value per share (NAV). The Fund's NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's individual investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market. 

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2026 to May 31, 2026           

Year-to-date Cumulative Total Return1

14.32 %

Cumulative Distribution Rate2

4.04 %

Five-year period ending May 31, 2026

Average Annual Total Return3

5.18 %

Current Annualized Distribution Rate4

8.09 %

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund's NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund's current fiscal period (January 1, 2026 through June 30, 2026) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund's NAV as of May 31, 2026.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending May 31, 2026. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of May 31, 2026.

Investors should consider the investment objectives, risks, charges and expense of the Fund carefully before investing. You can obtain the Fund's most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided here in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.  

Forward-Looking Statements
This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com
Symbol: (NYSE: CNS)

SOURCE Cohen & Steers Quality Income Realty Fund, Inc.

, /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date.

In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares. 

The Fund's monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund's assets. A return of capital is not taxable; rather, it reduces a shareholder's tax basis in his or her shares of the Fund.  The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund's distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund's distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

June 2026

YEAR-TO-DATE (YTD)

June 30, 2026*

Source

Per Share
Amount

% of Current
Distribution

Per Share
Amount

% of 2026
Distributions

Net Investment Income

$0.0000

0.00 %

$0.1821

34.89 %

Net Realized Short-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Net Realized Long-Term Capital Gains

$0.0870

100.00 %

$0.3399

65.11 %

Return of Capital (or other Capital Source)

$0.0000

0.00 %

$0.0000

0.00 %

Total Current Distribution

$0.0870

100.00 %

$0.5220

100.00 %

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy.  The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund's Year-to-date Cumulative Total Return for fiscal year 2026 (January 1, 2026 through May 31, 2026) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund's Cumulative Distribution Rate for 2026. In addition, the Fund's Average Annual Total Return for the five-year period ending May 31, 2026 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund's Current Annualized Distribution Rate for 2026. The performance and distribution rate information disclosed in the table is based on the Fund's net asset value per share (NAV). The Fund's NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's individual investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market. 

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2026 to May 31, 2026                                                                           

Year-to-date Cumulative Total Return1

7.91 %

Cumulative Distribution Rate2

3.78 %

Five-year period ending May 31, 2026

Average Annual Total Return3

8.70 %

Current Annualized Distribution Rate4

7.57 %

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund's NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund's current fiscal period (January 1, 2026 through June 30, 2026) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund's NAV as of May 31, 2026.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending May 31, 2026. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of May 31, 2026.

Investors should consider the investment objectives, risks, charges and expense of the Fund carefully before investing. You can obtain the Fund's most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided here in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.  

Forward-Looking Statements
This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com
Symbol: (NYSE: CNS)

SOURCE Cohen & Steers Closed-End Opportunity Fund, Inc.

, /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date.

In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares. 

The Fund's monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund's assets. A return of capital is not taxable; rather, it reduces a shareholder's tax basis in his or her shares of the Fund. In addition, distributions from the Fund's investments in MLPs are attributed to various sources, including net investment income and return of capital. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund's distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund's distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

June 2026

YEAR-TO-DATE (YTD)

June 30, 2026*

Source

Per Share
Amount

% of Current
Distribution

Per Share
Amount

% of 2026
Distributions

Net Investment Income

$0.1045

63.33 %

$0.4822

50.23 %

Net Realized Short-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Net Realized Long-Term Capital Gains

$0.0605

36.67 %

$0.4778

49.77 %

Return of Capital (or other Capital Source)

$0.0000

0.00 %

$0.0000

0.00 %

Total Current Distribution

$0.1650

100.00 %

$0.9600

100.00 %

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund's Year-to-date Cumulative Total Return for fiscal year 2026 (January 1, 2026 through May 31, 2026) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund's Cumulative Distribution Rate for 2026. In addition, the Fund's Average Annual Total Return for the five-year period ending May 31, 2026 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund's Current Annualized Distribution Rate for 2026. The performance and distribution rate information disclosed in the table is based on the Fund's net asset value per share (NAV). The Fund's NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's individual investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market. 

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2026 to May 31, 2026                                                                           

Year-to-date Cumulative Total Return1

13.08 %

Cumulative Distribution Rate2

3.42 %

Five-year period ending May 31, 2026

Average Annual Total Return3

8.70 %

Current Annualized Distribution Rate4

7.05 %

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund's NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund's current fiscal period (January 1, 2026 through June 30, 2026) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund's NAV as of May 31, 2026.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending May 31, 2026. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of May 31, 2026.

Investors should consider the investment objectives, risks, charges and expense of the Fund carefully before investing. You can obtain the Fund's most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided here in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.  

Forward-Looking Statements
This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com
Symbol: (NYSE: CNS)

SOURCE Cohen & Steers Infrastructure Fund, Inc.

Cohen & Steers, Inc. offers institutional-quality closed-end funds focused on real assets and alternative income, with a recent real estate sell-off creating attractive entry points. Fund sectors include real estate, preferred securities, infrastructure, utilities, and fixed income. C&S's expertise in alternatives, active management, and reliable monthly distributions make their CEFs excellent tools for diversification and steady income.

, /PRNewswire/ -- The Board of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for July, August and September 2026, as summarized in the charts below:

Ticker

Fund Name

Monthly
Dividend

FOF

Cohen & Steers Closed-End Opportunity Fund, Inc.

$0.087

LDP

Cohen & Steers Limited Duration Preferred and Income Fund, Inc.

$0.131

PSF

Cohen & Steers Select Preferred and Income Fund, Inc.

$0.126

PTA

Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund

$0.134

RFI

Cohen & Steers Total Return Realty Fund, Inc.

$0.080

RLTY

Cohen & Steers Real Estate Opportunities and Income Fund

$0.110

RNP

Cohen & Steers REIT and Preferred and Income Fund, Inc.

$0.136

UTF

Cohen & Steers Infrastructure Fund, Inc.

$0.165

Distributions will be made on the following schedule:

Month

Ex-Dividend/
Record Date

Payable Date

July

 Jul. 14, 2026

 Jul. 31, 2026

August

Aug. 11, 2026

Aug. 31, 2026

September

Sept. 8, 2026

Sept. 30, 2026

Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund, Cohen & Steers Real Estate Opportunities and Income Fund, Cohen & Steers Limited Duration Preferred and Income Fund, Inc., and Cohen & Steers Select Preferred and Income Fund, Inc. (each, a "Fund" and collectively the "Funds") pay regular monthly cash distributions to common shareholders at a level rate that may be adjusted from time to time. Each of these Funds' distributions reflect net investment income and may also include net realized capital gains and/or return of capital. Return of capital includes distributions paid by a fund in excess of its net investment income. Such excess is distributed from the fund's assets. Under federal tax regulations, some or all of the return of capital distributed by a fund may be taxed as ordinary income. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

Cohen & Steers Closed-End Opportunity Fund, Inc., Cohen & Steers Total Return Realty Fund, Inc., Cohen & Steers REIT and Preferred and Income Fund, Inc., and Cohen & Steers Infrastructure Fund, Inc. only:

Cohen & Steers Closed-End Opportunity Fund, Inc., Cohen & Steers Total Return Realty Fund, Inc., Cohen & Steers REIT and Preferred and Income Fund, Inc., and Cohen & Steers Infrastructure Fund, Inc. declared their monthly distributions pursuant to such Funds' managed distribution plans. Each Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The policy gives each Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. Information can also be found on the Funds' website at cohenandsteers.com. The Board of Directors of each Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of each Fund's shares.

Distributions of a Fund's investment in real estate investment trusts (REITs), master limited partnerships (MLPs) and/or closed-end funds (CEFs) may later be characterized as capital gains and/or a return of capital, depending on the character of the dividends reported to each Fund after year-end by the REITs, MLPs and CEFs held by a Fund.

Each Fund's distributions may include net investment income, long-term capital gains, short-term capital gains and/or return of capital. Under the plan, prior to the payment date of the distribution every month, each Fund will issue a press release and a notice containing information about the amount and sources of the distribution and other related information to shareholders of record on the record date. Please note that the notice is not provided for tax reporting purposes but for informational purposes only. Information can also be found on the Funds' website at cohenandsteers.com.

Shareholders should not use the information provided in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

Investors should consider the investment objectives, risks, charges and expense of a fund carefully before investing. You can obtain the Funds' most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

Forward-Looking Statements
This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com/
Symbol: (NYSE: CNS)

SOURCE Cohen & Steers, Inc.

Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans

June 24, 2026 07:00 ET  | Source: MapLight Therapeutics, Inc.

SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Martin Babler and Troy Cox to its Board of Directors following their election at the Company’s Annual Meeting of Stockholders on June 23, 2026. Mr. Babler and Mr. Cox succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who did not stand for re-election and have concluded their service on the Board. Mr. Babler has been appointed as a member of the Audit Committee, and Mr. Cox has been appointed Chair of the Nominating and Corporate Governance Committee.

“We are grateful to Rob and Jim for their years of leadership and service to MapLight, and we are pleased to welcome Martin and Troy to the Board. Both bring substantial strategic, operational and governance experience,” said Chris Kroeger, co-Founder and Chief Executive Officer of the Company. “Their proven leadership across biotechnology will support MapLight as we continue executing on our strategy to develop meaningful therapies for patients with CNS disorders.”

Mr. Babler has served as President, Chief Executive Officer and Chairman of the Board of Alumis Inc. since September 2021. He previously served as President and Chief Executive Officer of Principia Biopharma Inc. from 2011 until its acquisition by Sanofi S.A. in 2020, and as President and Chief Executive Officer of Talima Therapeutics, Inc. Earlier in his career, he held several leadership positions at Genentech, Inc., most notably as Vice President, Immunology Sales and Marketing. Mr. Babler currently serves on the board of directors of Prelude Therapeutics, Inc.

Mr. Cox previously served as President and Chief Executive Officer of Foundation Medicine, Inc. from 2017 to 2019, including through its acquisition by Roche in 2018. Prior to Foundation Medicine, he served as a Senior Vice President at Genentech, Inc. and held executive and senior leadership roles at UCB BioPharmaceuticals, including as President of CNS Operations, as well as at Sanofi-Aventis and Schering-Plough. Mr. Cox currently serves as Chair of the board of directors of SOPHiA GENETICS SA and on the boards of Standard BioTools Inc. and Fuze Health.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

For more information, please visit www.maplightrx.com.

Forward Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, the clinical development of meaningful therapies for CNS disorders. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, are intended to identify forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in the Company’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the Company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: the unpredictable relationship between preclinical study results and clinical study results; the risk that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials; the timing or likelihood of regulatory filings and approvals; expectations regarding the Company’s ability to fund its current operations; and other risks and uncertainties identified in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and subsequent disclosure documents the Company may file with the SEC. The Company claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

For investor inquiries: [email protected]

For media inquiries: [email protected]

-

Established biopharmaceutical executive with more than 25 years of business development, corporate strategy, financing, and transaction experience

Demonstrated leader in gene therapy and CNS drug development

Appointment comes as Latus enters the clinic, with LTS-201 for Huntington’s disease on track for IND submission in 3Q 2026

PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointment of Bethany Mancilla as Chief Business Officer. Ms. Mancilla brings a breadth of corporate development experience across large and small biotechnology companies, including an extensive history of transactions in gene therapy and central nervous system (CNS) disorders.

“Bethany joins Latus at a defining moment as we advance LTS-201 toward the clinic for Huntington’s disease and continue to build out our pipeline and partnering opportunities,” said P. Peter Ghoroghchian, M.D., Ph.D., Chief Executive Officer of Latus Bio. “Bethany has spent her career translating differentiated science into high-value transactions. Her leadership will be integral as we advance our strategy and pursue partnerships that extend the reach of our programs and platform for patients with high unmet needs.”

“Latus is at a true inflection point as it transitions into a clinical-stage company. LTS-201 represents a fundamentally differentiated approach to Huntington’s disease, targeting the somatic instability that drives disease progression while preserving the non-mutated allele,” said Ms. Mancilla. “Latus’ platform is built to scale precision gene therapy for larger patient populations, including multiple, potentially transformative, fast follow-programs and novel capsid opportunities. I look forward to working with the team to expanding our pipeline of disease modifying therapies through strategic partnerships.”

Prior to joining Latus, Ms. Mancilla served as Chief Business Officer at Capsida Biotherapeutics, a company developing next generation gene therapies, where she was responsible for corporate development, strategy, and partnerships and was successful in securing transactions that provided over $250 million in non-dilutive funding. Preceding Capsida, Ms. Mancilla held senior leadership positions at Cue Biopharma, Kite Pharma and Amgen. During more than six years at Amgen, she assumed escalating roles and responsibilities, culminating as Vice President of Business Development. In that role, she oversaw a global team responsible for licensing, co-development and M&A transactions across all modalities and therapeutic areas, including CNS. Prior to Amgen, Ms. Mancilla served as the Vice President of Business Development for Micromet, where she forged the strategic partnership that led to Amgen’s acquisition of the company. Throughout her career, she has developed strategy and business transactions with global pharmaceutical companies, including through leadership roles at PharmAthene and Gene Logic. Ms. Mancilla began her career as Director of Business Development for BCM Technologies, the for-profit subsidiary of Baylor College of Medicine, where she helped support the creation and financing of four biotechnology startup companies. She received her M.B.A. from the University of Houston and B.A. from the University of Colorado.

About Latus Bio

Latus is a biotechnology company dedicated to addressing devastating CNS and peripheral diseases via innovative and scalable gene therapies. The Company is advancing a broad therapeutics pipeline based on novel AAV capsid variants with potency and specificity. Latus is powered by a diverse team of visionary scientists, experienced clinicians, and leading industry executives. The Company has offices in Philadelphia, PA and in the Seaport in Boston, MA. For more information, visit www.latusbio.com.

Back to Newsroom

, /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS), today announced it is partnering with J.P. Morgan to provide access to the Cohen & Steers SICAV Short Duration Hybrid Credit & Income Fund for investors outside the United States across J.P. Morgan's global wealth management platform, offering their clients a cash alternative.

The Cohen & Steers SICAV Short Duration Hybrid Credit & Income Fund seeks to provide investors with high current income as the primary objective, and capital preservation as a secondary objective, through investments in global hybrid credit securities, while targeting a weighted average duration of less than three years. Hybrid credit securities offer investment opportunities with higher yields than similarly rated bonds. By targeting low duration securities, the Fund seeks to reduce portfolio interest-rate sensitivity.

Elaine Zaharis‑Nikas, Head of Fixed Income & Preferred Securities at Cohen & Steers, said: "Hybrid credit continues to stand out as a compelling source of high‑quality income, particularly for investors seeking resilience in a shifting rate environment. Our short‑duration approach is designed to help investors harvest attractive yields while mitigating interest‑rate sensitivity, and we are excited to bring this capability to more investors through our partnership with J.P. Morgan."

David Conway, Head of International Wholesale Distribution at Cohen & Steers, said:
"We are pleased to partner with one of the world's largest and most highly regarded banks and asset management organizations. As pioneers in hybrid credit strategies, today's announcement highlights the broader industry shift towards greater diversification within fixed income portfolio allocations."

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

This is a marketing communication. Please refer to the prospectus of the Cohen & Steers SICAV and to the relevant KIID/KID before making any final investment decisions. These documents are available free of charge on the Cohen & Steers website.

About Cohen & Steers SICAV Funds. The Funds are sub-funds of Cohen & Steers SICAV, a Luxembourg-domiciled undertaking for collective investment in transferrable securities (UCITS). Shares of the Funds are only offered pursuant to the current prospectus and the sales of shares of the Funds may be restricted in certain jurisdictions. The Funds have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or under any applicable securities laws of any state or other jurisdiction of the United States. The Funds are not registered under the U.S. Investment Company Act of 1940. Shares may not be offered or sold, directly or indirectly in the United States or to U.S. persons, as more fully described in the Funds' prospectus. This document does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States. Please see the prospectus for additional information including important risk considerations, potential loss of capital, and details about fees and expenses. Past performance is no guarantee of future results.

Potential Risks: Investment risk including possible loss of entire amount invested. Increased credit risk due to subordination to all other types of corporate debt. Default risk because the issuer experiences a decline in its financial status. Contingent Convertible Securities ("CoCos") are typically subject to greater levels of credit and liquidity risk. Call risk can cause the sub-fund to invest in lower yielding securities. Increases in interest rates may cause process to fall. Foreign security risk due to currency fluctuations, lower liquidity, political and economic uncertainties and differences in accounting standards. Subject to liquidity risk.

Website: https://www.cohenandsteers.com
Symbol:NYSE: CNS

SOURCE Cohen & Steers, Inc.

, /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced that Amit Muni has been appointed as Executive Vice President and Chief Financial Officer, effective June 8, 2026. Mr. Muni will lead the firm's financial operations, financial strategy and investor relations. He will join the firm's Executive Committee and report to Joseph Harvey, Chief Executive Officer.

Mr. Muni succeeds Michael Donohue, who has been serving as Interim Chief Financial Officer since October 17, 2025. Mr. Donohue will remain Interim Chief Financial Officer until June 8, 2026, after which time he will continue in his role as Controller.

Joseph Harvey, Chief Executive Officer, said:
"Amit brings more than two decades of leadership across public markets, asset and wealth management, and capital markets, with a strong track record of driving strategic growth, executing M&A and financing initiatives, and engaging with the investor community. His experience will be valuable in advancing our strategy as we continue to expand our global real assets platform, grow in the wealth channel, build our private markets capabilities and deliver long-term value for shareholders.

I also want to recognize and thank Mike Donohue for his dedicated leadership as interim CFO, successfully managing and improving the finance department and helping lead Cohen & Steers through a return to organic growth while implementing growth initiatives."

Mr. Muni joins the firm from CI Financial Corp., where he served as Chief Financial Officer of the $550+ billion AUM Canadian-based wealth and asset management firm. Prior to joining CI Financial Corp. in 2021, he was Chief Financial Officer at WisdomTree, Inc. Mr. Muni's experience also includes senior finance and accounting roles at the International Securities Exchange (ISE), Instinet Group, PricewaterhouseCoopers and National Securities Clearing Corporation.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

Website: https://www.cohenandsteers.com
Symbol:NYSE: CNS

Forward-Looking Statements
This press release and other statements that Cohen & Steers may make may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect the Company's current views with respect to, among other things, the Company's operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "may," "will," "should," "seeks," "predicts," "intends," "plans," "estimates," "anticipates" or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these forward-looking statements. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

SOURCE Cohen & Steers, Inc.

, /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of the distribution to be paid on May 29, 2026 and cumulative distributions paid fiscal year-to-date.

In December 2011, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares. 

The Fund's monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund's assets. A return of capital is not taxable; rather, it reduces a shareholder's tax basis in his or her shares of the Fund. In addition, distributions from the Fund's investments in real estate investment trusts (REITs) may later be characterized as capital gains and/or a return of capital, depending on the character of the dividends reported to the Fund after year-end by REITs held by the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund's distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund's distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

May 2026

YEAR-TO-DATE (YTD)

May 31, 2026*

Source

Per Share Amount

% of Current Distribution

Per Share Amount

% of 2026 Distributions

Net Investment Income

$0.0282

35.25 %

$0.1098

27.45 %

Net Realized Short-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Net Realized Long-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Return of Capital (or other Capital Source)

$0.0518

64.75 %

$0.2902

72.55 %

Total Current Distribution

$0.0800

100.00 %

$0.4000

100.00 %

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy. The Fund estimates that it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with 'yield' or 'income'. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund's Year-to-date Cumulative Total Return for fiscal year 2026 (January 1, 2026 through April 30, 2026) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund's Cumulative Distribution Rate for 2026. In addition, the Fund's Average Annual Total Return for the five-year period ending April 30, 2026 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund's Current Annualized Distribution Rate for 2026. The performance and distribution rate information disclosed in the table is based on the Fund's net asset value per share (NAV). The Fund's NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's individual investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market. 

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2026 to April 30, 2026

Year-to-date Cumulative Total Return1

11.19 %

Cumulative Distribution Rate2

3.36 %

Five-year period ending April 30, 2026

Average Annual Total Return3

4.39 %

Current Annualized Distribution Rate4

8.06 %

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund's NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund's current fiscal period (January 1, 2026 through May 31, 2026) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund's NAV as of April 30, 2026.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending April 30, 2026. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of April 30, 2026.

Investors should consider the investment objectives, risks, charges and expense of the Fund carefully before investing. You can obtain the Fund's most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided here in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.  

Forward-Looking Statements

This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com
Symbol: (NYSE: CNS)

SOURCE Cohen & Steers Total Return Realty Fund, Inc.

, /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on May 29, 2026 and cumulative distributions paid fiscal year-to-date.

In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares. 

The Fund's monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund's assets. A return of capital is not taxable; rather, it reduces a shareholder's tax basis in his or her shares of the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund's distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund's distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

May 2026

YEAR-TO-DATE (YTD)
May 31, 2026*

Source

Per Share
Amount

% of Current
Distribution

Per Share
Amount

% of 2026
Distributions

Net Investment Income

$0.0334

38.39 %

$0.1978

45.47 %

Net Realized Short-Term Capital Gains

$0.0000

0.00 %

$0.0000

0.00 %

Net Realized Long-Term Capital Gains

$0.0536

61.61 %

$0.2372

54.53 %

Return of Capital (or other Capital Source)

$0.0000

0.00 %

$0.0000

0.00 %

Total Current Distribution

$0.0870

100.00 %

$0.4350

100.00 %

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund's Year-to-date Cumulative Total Return for fiscal year 2026 (January 1, 2026 through April 30, 2026) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund's Cumulative Distribution Rate for 2026. In addition, the Fund's Average Annual Total Return for the five-year period ending April 30, 2026 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund's Current Annualized Distribution Rate for 2026. The performance and distribution rate information disclosed in the table is based on the Fund's net asset value per share (NAV). The Fund's NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund's investment performance, it does not measure the value of a shareholder's individual investment in the Fund. The value of a shareholder's investment in the Fund is determined by the Fund's market price, which is based on the supply and demand for the Fund's shares in the open market. 

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2026 to April 30, 2026

Year-to-date Cumulative Total Return1

6.22 %

Cumulative Distribution Rate2

3.18 %

Five-year period ending April 30, 2026

Average Annual Total Return3

8.80 %

Current Annualized Distribution Rate4

7.64 %

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund's NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund's current fiscal period (January 1, 2026 through May 31, 2026) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund's NAV as of April 30, 2026.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending April 30, 2026. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of April 30, 2026.

Investors should consider the investment objectives, risks, charges and expense of the Fund carefully before investing. You can obtain the Fund's most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission's EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided here in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.  

Forward-Looking Statements
This press release and other statements that Cohen & Steers may make may contain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect the company's current views with respect to, among other things, its operations and financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates," or the negative versions of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties.

Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Website: https://www.cohenandsteers.com
Symbol: (NYSE: CNS)

SOURCE Cohen & Steers Closed-End Opportunity Fund, Inc.

, /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced that three funds of the Cohen & Steers SICAV – the Global Listed Infrastructure Fund, the Global Real Estate Securities Fund, and the Diversified Real Assets Fund (the "funds") – have received approval under Section 65 of the Collective Investment Schemes Control Act (CISCA) from South Africa's Financial Sector Conduct Authority (FSCA).

The Section 65 approval permits the funds to be marketed and distributed to eligible investors in South Africa, subject to applicable regulatory requirements.

Sean Cooney, Head of U.K. Wealth, said:
"We continue to see strong client interest from South African investors seeking broader diversification, inflation protection, and alternative sources of return within their global allocations. We are pleased to offer direct access to several of our key real asset strategies, helping investors build stronger, more resilient global portfolios."

David Conway, Head of International Wholesale Distribution, said:
"As a specialist in real assets, we are excited to register our fund offerings in South Africa. Over the past five years, we have grown our SICAV (UCITS) assets by more than 500%, with our funds now available across the UK, EMEA, and Asia. Expanding into South Africa represents a natural progression of our international strategic growth plan, further strengthening our client partnerships and increasing assets under management".

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

Collective Investment Schemes in Securities (CIS) should be considered as medium to long-term investments. The value may go up as well as down and past performance is not necessarily a guide to future performance. CISs are traded at the ruling price and can engage in scrip lending and borrowing. A schedule of fees, charges and maximum commissions is available on request from the Manager. A CIS may be closed to new investors in order for it to be managed more efficiently in accordance with its mandate. Performance has been calculated using net NAV to NAV numbers with income reinvested. There is no guarantee in respect of capital or returns in a portfolio. Representative Office: Prescient Management Company (RF) (Pty) Ltd is registered and approved under the Collective Investment Schemes Control Act (No.45 of 2002). For any additional information such as fund prices, fees, brochures, minimum disclosure documents and application forms please go to cohenandsteers.com.

This is a marketing communication. Please refer to the prospectus of the Cohen & Steers SICAV and to the relevant KIID/KID before making any final investment decisions. These documents are available free of charge on the Cohen & Steers website.

Website: https://www.cohenandsteers.com
Symbol:NYSE: CNS

, /PRNewswire/ -- Cohen & Steers Income Opportunities REIT, Inc. ("CNSREIT") announced today its acquisition of Oracle Crossings, a 266,000‑square‑foot, grocery‑anchored open‑air shopping center located in the Oro Valley submarket of Tucson, Arizona. The acquisition was completed through CNSREIT's programmatic joint venture with Phillips Edison & Company (NASDAQ: PECO – "PECO"), a publicly traded owner and operator of grocery‑anchored U.S. shopping centers.

Oracle Crossings is 96% leased and anchored by Sprouts Farmers Market and HomeGoods. The center benefits from a highly visible location at the intersection of Oracle Road and Magee Road, which sees 66,000 vehicles per day. The center attracts more than 2.1 million annual visitors.

The property sits within Oro Valley, which is adjacent to Tucson's most affluent and fastest‑growing suburbs. The broader Tucson metro area has experienced 1.2% annual population growth and 3.7% annual median household income growth over the past three years—both above U.S. averages—supported by a diversified economic base including the University of Arizona, Raytheon, Davis‑Monthan Air Force Base, and Banner Health.

James S. Corl, Chief Executive Officer of CNSREIT and Head of the Private Real Estate Group at Cohen & Steers, said:
"Oracle Crossings is exactly the type of necessity‑anchored, high‑quality retail asset we seek to own in CNSREIT. Tenants demonstrate strong performance, and the property's location in one of Tucson's most affluent and supply‑constrained submarkets provides a compelling foundation for durable income and long‑term growth. Open‑air shopping centers continue to benefit from limited new supply, strong tenant balance sheets, and resilient consumer demand—conditions that we believe position Oracle Crossings as a highly attractive addition to our portfolio."

CNSREIT is acquiring high-quality properties that seek to generate attractive income potential alongside best-in-class operators and has a current focus on well-anchored, necessity-driven shopping centers. Open-air shopping centers are at their highest occupancy level of the past 16 years at 95.7%1, according to real estate analytics provider CoStar Group.

About CNSREIT. Cohen & Steers Income Opportunities REIT, Inc. is a perpetual-life, non-listed REIT formed to invest primarily in high quality, income-focused, stabilized properties within the United States. CNSREIT is externally managed by Cohen & Steers Capital Management, Inc., a subsidiary of Cohen & Steers, Inc.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.

About Phillips Edison & Company.
Phillips Edison & Company, Inc. ("PECO") is one of the nation's largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers. Founded in 1991, PECO has generated strong results through its vertically-integrated operating platform and national footprint of well-occupied shopping centers. PECO's centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO's top grocery anchors include Kroger, Publix, Albertsons and Ahold Delhaize. As of March 31, 2026, PECO managed 326 shopping centers, including 299 wholly-owned centers comprising 33.7 million square feet across 31 states and 27 shopping centers owned in three institutional joint ventures. PECO is focused on creating great omni-channel, grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time. Learn more at www.phillipsedison.com.

Forward-Looking Statements
This press release contains forward looking statements within the meaning of the federal securities laws. These forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "anticipate," "estimate," "believe," "continue," "identified" or other similar words or the negatives thereof. These may include CNSREIT's financial projections and estimates and their underlying assumptions, statements about plans, objectives and expectations with respect to future operations, statements with respect to acquisitions, statements regarding future performance and statements regarding identified but not yet closed acquisitions. Such forward-looking statements are inherently uncertain and there are or may be important factors that could cause actual outcomes or results to differ materially from those indicated in such statements. CNSREIT believes these factors also include but are not limited to those described under the section entitled "Risk Factors" in the prospectus, as amended and supplemented from time to time, filed with the Securities and Exchange Commission (the "SEC"), which is accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this document. Except as otherwise required by federal securities laws, CNSREIT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

1 Source: CoStar

SOURCE Cohen & Steers Income Opportunities REIT, Inc.

Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2

Access the segment here

HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.

Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation. The conversation explored investor reception to the Company's evolving strategy, the significance of participation from leading healthcare-focused institutional investors and how the strengthened balance sheet enhances CNS Pharmaceuticals' ability to pursue potential transformational opportunities. Mr. O'Loughlin also discussed the importance of institutional support and the Company's long-term vision for creating shareholder value as it advances its next phase of growth.

The Virtual Investor "What This Means" segment is available for on-demand viewing here.

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]

Business Development Contact
CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
[email protected]

SOURCE: CNS Pharmaceuticals, Inc.

, /PRNewswire/ -- Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") announced today that its Board of Directors has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Fund's common stock (par value $0.001 per share), as of the record date, June 18, 2026 (the "Record Date"). Holders of these Rights will be entitled to subscribe for additional shares of common stock (the "Offer"). The Offer to acquire additional shares of common stock will be made only by means of a prospectus supplement and accompanying prospectus, and this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any of the Fund's securities.

Cohen & Steers Capital Management, Inc. (the "Advisor") believes that incremental investments in key sectors within listed and private real estate can potentially support the distribution rate and enhance portfolio performance for all common stockholders.

Mathew Kirschner, Portfolio Manager, U.S. Real Estate at Cohen & Steers, said:
"We believe listed and private real estate are attractively valued compared with stocks and bonds, reflecting the idea that real estate has repriced and is in the early stages of a new cycle. Powerful themes—a retail renaissance, digital transformation, and aging populations—are converging with limited supply to create compelling investment opportunities across real estate. This rights offering provides investors with the potential to capitalize on these opportunities."

A portion of the proceeds from the Offer may be allocated to investments in private commercial real estate but will typically not exceed 10% of the Fund's managed assets.  Additionally, the Offer provides potential to invest in new opportunities without the need to sell existing portfolio positions, which may reduce taxable events for common stockholders. It also creates potential for increased liquidity and trading volume of the Fund's shares of common stock as well as providing common stockholders an opportunity to buy new common shares below market price. Importantly, the Advisor (and not the Fund) will pay all offering expenses, including the solicitation and dealer manager fees, in support of the Offer.

Certain key terms of the Offer are as follows:

Common stockholders on the Record Date ("Record Date Stockholders") will receive one transferable Right for each share of common stock owned. Three Rights are required to purchase one newly issued share of common stock at the Subscription Price (defined below). The Fund will not issue fractional shares, so Record Date Stockholders holding fewer than three Rights will be entitled to subscribe for one full share of common stock. The Subscription Price will be determined by the Fund upon the expiration of the Offer, which is currently expected to be July 15, 2026, unless the Fund extends the Offer (the "Expiration Date"). The Subscription Price will be based upon a formula equal to the higher of 92.5% of the average market price on Expiration Date and the four preceding trading days on the NYSE or 90% of the average of net asset value on Expiration Date and the four preceding trading days (the "Subscription Price"). Record Date Stockholders who fully exercise all Rights initially issued to them will be permitted to subscribe for additional shares of common stock that were not subscribed for by other Record Date Stockholders at the Subscription Price ("over-subscription privilege"). Investors who are not Record Date Stockholders, but who otherwise acquire Rights, are not entitled to subscribe for any additional shares of common stock. Over-subscription shares may only be acquired if there are unexercised Rights.  If sufficient shares of common stock are not available to honor all over-subscription requests, unsubscribed shares of common stock will be allocated pro rata among those Record Date Stockholders who over-subscribe based on the number of shares of common stock they owned on the Record Date. The Rights are expected to trade "when issued" on the NYSE beginning on June 17, 2026, and the Fund's shares of common stock are expected to trade "ex-Rights" on the NYSE beginning on June 18, 2026. The Rights are expected to begin trading for normal settlement on the NYSE (NYSE: RQI RT) on or about June 22, 2026. The Offer is expected to expire at 5:00 PM Eastern Time on July 15, 2026, unless extended. The definitive terms of the Offer will be made through a prospectus supplement and accompanying prospectus. The final terms of the Offer may be different from those set out above. All offering expenses, including sales commissions, will be borne by the Advisor and not the Fund or any of the Fund's common stockholders. The Fund expects to maintain its current distribution level following the Offer. The Fund has declared a monthly distribution of $0.090 per share of common stock payable on June 30, 2026, with a record date of June 9, 2026, and a monthly distribution of $0.090 per share of common stock payable on July 31, 2026, with a record date of July 6, 2026. Any shares of common stock issued as a result of the Offer will not be record date shares for the Fund's monthly distribution to be paid on June 30, 2026 or July 31, 2026, and will not be entitled to receive such distribution.

The Fund expects to mail subscription certificates evidencing the Rights and a copy of the prospectus supplement and accompanying prospectus for the Offer to Record Date Stockholders within the United States shortly following the Record Date. Inquiries regarding the Offer should be directed to the Information Agent, Georgeson LLC at 888 812-7762.

Record Date Stockholders who hold shares of common stock through a broker, custodian or trust company can most likely act electronically and should contact such entity to understand their procedure to exercise or sell their Rights as each firm may have different procedures. Please review the offering materials carefully and ensure any decisions are made within the subscription period, and according to your broker's, custodian, or trust company's specific closing date, which may be earlier than Expiration Date.

Record Date Stockholders who do not hold shares of common stock through a broker, custodian, or trust company should forward their instructions to either exercise or sell their Rights by completing the subscription certificate and delivering it to the subscription agent for the Offer, together with their payment, at one of the locations indicated on the subscription certificate or in the prospectus supplement.

The information in this press release is not complete and is subject to change. This document is not an offer to sell any securities and is not soliciting an offer to buy any securities in any jurisdiction where the offer or sale is not permitted. This document is not an offering, which can only be made by a prospectus. Investors should consider the Fund's investment objectives, risks, charges, and expenses carefully before investing. The Fund's prospectus supplement and accompanying prospectus will contain this and additional information about the Fund and additional information about the Offer and should be read carefully before investing. For further information regarding the Offer, or to obtain a prospectus supplement and the accompanying prospectus, when available, please contact the Fund's information agent:

Georgeson LLC
51 West 52nd Street, 6th Floor
New York, NY 10019
(888) 812-7762

About Cohen & Steers Quality Income Realty Fund, Inc. The Fund is a diversified, closed-end management investment company registered under the Investment Company Act of 1940, as amended. The primary investment objective of the Fund is to seek high current income through investment in real estate securities. The secondary investment objective is capital appreciation. Real estate securities include common stocks, preferred stocks and other equity and debt securities issued by real estate companies, including real estate investment trusts (REITs) and similar REIT-like entities.

About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo, and Singapore.

The Advisor is a wholly owned subsidiary of Cohen & Steers.

Safe Harbor Statement 
This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

Forward-Looking Statements
This press release contains certain statements that may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included herein are "forward-looking statements." Although the Fund and the Advisor believe the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Fund's reports that are filed with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required by law, the Fund and the Advisor do not assume a duty to update any forward-looking statement.

Risks of Investing in Real Estate Securities.
The risks of investing in real estate securities are similar to those associated with direct investments in real estate, including falling property values due to increasing vacancies; declining rents resulting from economic, legal, political or technological developments; lack of liquidity; lack of availability of financing; limited diversification, sensitivity to certain economic factors such as interest rate changes and market recessions and changes in supply of or demand for similar properties in a given market. No representation or warranty is made as to the efficacy of any particular strategy or fund or the actual returns that may be achieved.

Risks of Investing in Closed-End Funds
Shares of many closed-end funds frequently trade at a discount from their asset value. Funds are subject to stock market risk, which is the risk that stock prices overall will decline over short or long periods, adversely affecting the value of an investment in a fund. The Offer may result in an immediate dilution of the net asset value per share of common stock for all existing common stockholders, including those who fully exercise their Rights.

Website: https://www.cohenandsteers.com

SOURCE Cohen & Steers, Inc.

June 11, 2026 07:00 ET  | Source: Relmada Therapeutics

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development will be instrumental in advancing sepranolone, Relmada’s GABAA receptor modulator program targeting Prader-Willi Syndrome and other CNS indications.

“We are very pleased to welcome Mike to the Relmada team. His distinguished career in CNS drug discovery and development, including his leadership of research and scientific strategy at Sage Therapeutics, gives him a unique and highly relevant perspective on neuroactive steroid biology that we believe will be invaluable to the sepranolone program,” said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics.

“Sepranolone's mechanism of action – selectively antagonizing the effects of allopregnanolone at GABA-A receptors without broadly disrupting GABAergic signaling – represents a precise and elegant approach to modulating neural circuits that are dysregulated in compulsivity-related disorders like Prader-Willi syndrome,” said Dr. Quirk, Senior Advisor – Sepranolone Program. “I believe sepranolone has the potential to be a genuinely differentiated medicine for patients who currently have very limited options. I am excited to join the Relmada team and contribute to advancing this program toward clinical proof-of-concept.”

About Michael Quirk, PhD

Michael Quirk is a trained neurophysiologist and translational scientist with 20 years of diverse biopharmaceutical industry experience. Most recently, Mike served as Chief Scientific Officer and interim Head of R&D at Sage Therapeutics (Sage) where he worked on the first medicines approved for the treatment of Postpartum Depression and helped to build a portfolio targeting a range of brain health conditions with a specific interest in indications at the intersection of neuroscience and women’s health.

Prior to joining Sage in 2014, Mike was a Director within the Neuroscience Innovative Medicine group at AstraZeneca working on a variety of programs within psychiatry and neurology.

Mike holds both an S.B. degree in Cognitive Science and a Ph.D. in Systems Neuroscience from the Massachusetts Institute of Technology and completed his post-doctoral training at Cold Spring Harbor Laboratory in New York studying neural mechanisms of decision-making and goal-directed behavior.

About Sepranolone and GABA Modulation

Sepranolone, a synthetic isoallopregnanolone, selectively modulates GABAA receptors by antagonizing allopregnanolone (ALLO), without disrupting GABA signaling. It targets disorders linked to excess GABAergic activity such as Prader-Willi syndrome, Tourette syndrome, and obsessive-compulsive disorder (OCD). More than 335 patients have been treated with sepranolone in clinical trials to date, with an excellent safety profile.

About Prader-Willi Syndrome (PWS)

PWS is a rare genetic disorder caused by chromosomal deletions on chromosome 15, leading to neurodevelopmental and behavioral complications. Global prevalence is estimated to be 350,000-400,000 patients. Current treatments address symptoms but do not modify the underlying neurobehavioral pathology.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Forward-Looking Statements:

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada’s product candidates to fail to progress, potential for Phase 2 NDV-01 data to fail to continue to deliver positive results supporting further development, potential for clinical trials to fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, or that future NDV-01 and/or sepranolone clinical results will be acceptable to the FDA, failure to secure adequate NDV-01 and/or sepranolone drug supply, failure of pending patent applications to result in issued patents, or issued patents being challenged and invalidated by third parties or not providing us with any competitive advantages, the Company’s cash runway and sufficiency of the Company’s cash resources and uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete list.

Investor Contact:
Brian Ritchie
LifeSci Advisors
[email protected]

Media Inquiries:
Corporate Communications
[email protected]